6 results on '"Gamble, Greg D."'
Search Results
2. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.
- Author
-
Bolland MJ, Grey A, Gamble GD, and Reid IR
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Diseases epidemiology, Calcium, Dietary therapeutic use, Endpoint Determination, Female, Humans, Male, Middle Aged, Neoplasms epidemiology, Randomized Controlled Trials as Topic, Vascular Diseases epidemiology, Bone Diseases prevention & control, Dietary Supplements, Neoplasms prevention & control, Vascular Diseases prevention & control, Vitamin D therapeutic use, Vitamins therapeutic use
- Abstract
Background: Vitamin D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of vitamin D on disorders are needed., Methods: We did a trial sequential meta-analysis of existing randomised controlled trials of vitamin D supplements, with or without calcium, to investigate the possible effect of future trials on current knowledge. We estimated the effects of vitamin D supplementation on myocardial infarction or ischaemic heart disease, stroke or cerebrovascular disease, cancer, total fracture, hip fracture, and mortality in trial sequential analyses using a risk reduction threshold of 5% for mortality and 15% for other endpoints., Findings: The effect estimate for vitamin D supplementation with or without calcium for myocardial infarction or ischaemic heart disease (nine trials, 48 647 patients), stroke or cerebrovascular disease (eight trials 46 431 patients), cancer (seven trials, 48 167 patients), and total fracture (22 trials, 76 497 patients) lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk of any of these endpoints by 15% or more. Vitamin D supplementation alone did not reduce hip fracture by 15% or more (12 trials, 27 834 patients). Vitamin D co-administered with calcium reduced hip fracture in institutionalised individuals (two trials, 3853 patients) but did not alter the relative risk of hip fracture by 15% or more in community-dwelling individuals (seven trials, 46 237 patients). There is uncertainty as to whether vitamin D with or without calcium reduces the risk of death (38 trials, 81 173)., Interpretation: Our findings suggest that vitamin D supplementation with or without calcium does not reduce skeletal or non-skeletal outcomes in unselected community-dwelling individuals by more than 15%. Future trials with similar designs are unlikely to alter these conclusions., Funding: Health Research Council of New Zealand., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
3. Intensive Serum Urate Lowering With Oral Urate‐Lowering Therapy for Erosive Gout: A Randomized Double‐Blind Controlled Trial.
- Author
-
Dalbeth, Nicola, Doyle, Anthony J., Billington, Karen, Gamble, Greg D., Tan, Paul, Latto, Kieran, Parshu Ram, Thrishila, Narang, Ravi, Murdoch, Rachel, Bursill, David, Mihov, Borislav, Stamp, Lisa K., and Horne, Anne
- Subjects
OSTEORADIOGRAPHY ,BONE diseases ,GOUT suppressants ,BONES ,PAIN ,ORAL drug administration ,HEALTH status indicators ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,PHYSICAL activity ,COMPARATIVE studies ,BLIND experiment ,DESCRIPTIVE statistics ,SYMPTOMS ,QUALITY of life ,URIC acid ,STATISTICAL sampling ,COMPUTED tomography ,GOUT ,EVALUATION - Abstract
Objective: To determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout. Methods: We undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of ≥0.30 mmoles/liter at baseline. Participants were randomly assigned to either an intensive serum urate target of <0.20 mmoles/liter or a standard target of <0.30 mmoles/liter (considered the standard according to rheumatology guidelines). Oral serum urate–lowering therapy was titrated to target using a standardized protocol (with the maximum approved doses of allopurinol, probenecid, febuxostat, and benzbromarone). The primary end point was the total computed tomography (CT) bone erosion score. Outcome Measures in Rheumatology (OMERACT) gout core outcome domains were secondary end points. Results: Although the serum urate levels were significantly lower in the intensive target group compared to the standard target group over the study period (P = 0.002), fewer participants in the intensive target group achieved the randomized serum urate target level by year 2 (62% versus 83% of patients in the standard target group; P < 0.05). The intensive target group required higher doses of allopurinol (mean ± SD 746 ± 210 mg/day versus 497 ± 186 mg/day; P < 0.001) and received more combination therapy (P = 0.0004) compared to the standard target group. We observed small increases in CT bone erosion scores in both serum urate target groups over 2 years, with no between‐group difference (P = 0.20). OMERACT core outcome domains (gout flares, tophi, pain, patient's global assessment of disease activity, health‐related quality of life, and activity limitation) improved in both groups over 2 years, with no between‐group differences. Adverse event and serious adverse event rates were similar between the groups. Conclusion: Compared to a serum urate target of <0.30 mmoles/liter, more intensive serum urate lowering is difficult to achieve with an oral urate‐lowering therapy. Intensive serum urate lowering leads to a high medication burden and does not improve bone erosion scores in patients with erosive gout. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Bone erosions in patients with chronic gouty arthropathy are associated with tophi but not bone oedema or synovitis: new insights from a 3 T MRI study.
- Author
-
McQueen, Fiona M., Doyle, Anthony, Reeves, Quentin, Gao, Angela, Tsai, Amy, Gamble, Greg D., Curteis, Barbara, Williams, Megan, and Dalbeth, Nicola
- Subjects
MAGNETIC resonance imaging ,ACADEMIC medical centers ,BONE diseases ,CONFIDENCE intervals ,EPIDEMIOLOGY ,GOUT ,RESEARCH funding ,STATISTICS ,LOGISTIC regression analysis ,DATA analysis ,INTER-observer reliability ,CONTRAST media ,DATA analysis software ,DESCRIPTIVE statistics ,THERAPEUTICS - Abstract
Objectives. Bone erosion has been linked with tophus deposition in gout but the roles of osteitis (MRI bone oedema) and synovitis remain uncertain. Our aims in this prospective 3 T MRI study were to investigate the frequency of these features in gout and determine their relation to one another.Methods. 3 T MRI scans of the wrist were obtained in 40 gout patients. Scans were scored independently by two radiologists for bone oedema, erosions, tophi and synovitis. Dual-energy CT (DECT) scans were scored for tophi in a subgroup of 10 patients.Results. Interreader reliability was high for erosions and tophi [intraclass correlation coefficients (ICCs) 0.77 (95% CI 0.71, 0.87) and 0.71 (95% CI 0.52, 0.83)] and moderate for bone oedema [ICC = 0.60 (95% CI 0.36, 0.77)]. Compared with DECT, MRI had a specificity of 0.98 (95% CI 0.93, 0.99) and sensitivity of 0.63 (95% CI 0.48, 0.76) for tophi. Erosions were detected in 63% of patients and were strongly associated with tophi [odds ratio (OR) = 13.0 (95% CI 1.5, 113)]. In contrast, no association was found between erosions and bone oedema. Using concordant data, bone oedema was scored at 6/548 (1%) sites in 5/40 patients (12.5%) and was very mild (median carpal score = 1, maximum = 45). In logistic regression analysis across all joints nested within individuals, tophus, but not synovitis, was independently associated with erosion [OR = 156.5 (21.2, >999.9), P < 0.0001].Conclusion. Erosions were strongly associated with tophi but not bone oedema or synovitis. MRI bone oedema was relatively uncommon and low grade. These findings highlight the unique nature of the osteopathology of gout. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
5. 10-Year Probability of Recurrent Fractures Following Wrist and Other Osteoporotic Fractures in a Large Clinical Cohort: An Analysis From the Manitoba Bone Density Program.
- Author
-
Hodsman, Anthony B., Leslie, William D., Tsang, James F., and Gamble, Greg D.
- Subjects
MEDICAL research ,BONE fractures ,BONE injuries ,CARPAL bones ,BONE diseases ,ARM fractures ,MEDICAL care ,OSTEOPOROSIS ,BONE density ,WOUNDS & injuries - Abstract
The article reports on the study that investigates the probability of recurrent osteoporotic fractures after a primary wrist fracture with other important primary fracture sites. The study evaluates the longitudinal health service records for the presence of fracture codes before and after bone mineral density (BMD) testing. It found that wrist fractures are the most common of the clinical osteoporotic fractures in patients referred for BMD testing. However, it reveals that the risk of recurrent fractures in the 10 years following a wrist fracture is substantially lower than the other osteoporotic fractures.
- Published
- 2008
- Full Text
- View/download PDF
6. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
- Author
-
Bolland, Mark J., Grey, Andrew B., Horne, Anne M., Briggs, Simon E., Thomas, Mark G., Ellis-Pegler, Rod B., Woodhouse, Andrew F., Gamble, Greg D., and Reid, Ian R.
- Subjects
HIV-positive men ,BONE density ,HIGHLY active antiretroviral therapy ,HUMAN body composition ,OSTEOPENIA ,OSTEOPOROSIS ,BONE diseases - Abstract
Objective Recently we reported that human immunodeficiency virus (HIV)-infected Caucasian men treated with highly active antiretroviral therapy (HAART) have normal weight-adjusted bone mineral density (BMD), in contrast to most other cross-sectional analyses, which have reported low BMD in HIV-infected patients. We have now addressed the question of whether there is accelerated BMD loss over time in HIV-infected men. Design A 2-year, prospective, longitudinal study. Subjects Twenty-three HAART-treated, HIV-infected men and 26 healthy controls. Measurements All participants had measurements of BMD and bone-related laboratory parameters at baseline, and a repeat measurement of BMD at 2 years. Results In the HIV-infected men the mean age was 47 years, the mean duration of infection was 8·2 years, and the mean duration of HAART was 54 months. Over 2 years of follow-up, BMD increased from baseline in the HIV-infected men by 2·6% at the lumbar spine ( P = 0·05 vs. baseline), and remained stable at the total hip (mean change 0·1%, P > 0·99) and total body (mean change 0·6%, P = 0·39). Mean changes in BMD in the control group were 1·4% at the lumbar spine, –0·1% at the total hip, and –0·8% at the total body. The HIV-infected men lost less total body BMD than the control group ( P = 0·01). In the HIV-infected men, body weight remained stable over 2 years while fat mass decreased and lean mass tended to increase, whereas in the controls, body weight and fat mass increased while lean mass remained stable. Conclusions Accelerated bone loss does not occur in HIV-infected men treated with HAART. Monitoring of BMD in HIV-infected men may not be necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.